Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. Activated effector T-cells, which kill cancer cells, can be affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2. PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e. interferon gamma) or intrinsic signals, such as genetic aberrations involving 9p24.1, latent Epstein-Barr virus infection, PD-L1 3′-untranslated region disruptions, and activated Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Anti-PD-1 therapy improves the overall response rate to treatment in patients with lymphoid neoplasms, particularly relapsed/refractory classical Hodgkin lymphoma. Inspired by their success in treating patients with classical Hodgkin lymphoma, medical practitioners have expanded PD-1 therapy, given as a single therapy or in combination with other drugs, to patients with other types of lymphoma. In this review, current clinical trials with anti-PD-1 or anti-PD-L1 drugs are summarized. The results of numerous clinical trials will broaden our understanding of PD-1 pathway and shall expand the list of patients who will get benefit from these agents including those who suffer from lymphoid neoplasms.
Introduction
T cell activation is explained by the two-signal model proposed by Bretscher and Cohn (Figure 1 ). [1] The first signal, which triggers T cell receptor (TCR) signaling, occurs when the major histocompatibility complex (MHC) molecule of an antigen-presenting cell (APC) presents a processed antigen to the TCR of a T cell. The second signal, which is an antigenindependent, co-stimulatory or co-inhibitory signal delivered by the APCs, modulates TCR signaling and determines the T cell's fate. The prototypical molecule of the second signal is CD28, which constitutively expressed in resting naïve T-cells. [2] CD28's ligands (such as B7-1 or B7-2) induce cell-cycle progression, interleukin-2 (IL-2) production, and clonal expansion. If T cells do not receive co-stimulatory second signals from molecules like CD28, they become anergic. In contrast, cytotoxic T-lymphocyte antigen-4 (CTLA-4), which shares the same ligands with CD28, is a co-inhibitory receptor on T-cells that induces T-cell tolerance. [3] If T cells do not receive co-inhibitory second signals, fatal lymphoproliferation and multiorgan autoimmunity can occur in mice. [4] Additional secondsignal receptors and ligands, which are collectively called B7-CD28 family, have also been discovered and include programmed death ligand-1 (PD-L1) and PD-L2. Unlike B7-1 and B7-2, PD-L1 and PD-L2 do not bind to CD28 or CTLA-4. Instead, they bind to programmed death-1 (PD-1) on T-cells.
The PD-1 pathway has recently emerged as an attractive target in cancer immunotherapy. In the context of the cancer-immunity cycle, the aim of immunotherapy is to restore immune function at various steps of cancer-immunity cycle. Several clinical studies have shown that blocking the PD-1 pathway leads to significant responses in patients with various solid tumors. [5] Numerous clinical trials with PD-1 pathway blocking agents, used either alone or in combination with other therapies, are currently in progress. In this review, we discuss the functions of the PD-1 pathway in the cancer-immunity cycle, the armamentarium of PD-1 pathway blocking agents, current and prior clinical trials in patients with lymphoid malignancies and future directions in search.
The structure of PD-1, PD-L1, and PD-L2
PD-1 is a protein encoded by the 5-exon PDCD1 gene on chromosome 2q37.3. It consists of 288 amino acids, and its calculated molecular weight is 31.6 kDa. However, Agata et al's [6] immunoprecipitation of the protein revealed broad bands with molecular weights of 50-55 kDa, suggesting that the protein is heavily glycosylated. PD-1 contains a single immunoglobulin V-like domain, a transmembrane domain, and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosinebased switch motif (ITSM). [7, 8] Two PD-1ligands, PD-L1 and PD-L2, have structures similar to that of PD-1 in that they contain an immunoglobulin V-like domain, an immunoglobulin C-like domain, a transmembrane domain, and an intracellular domain. [9] These ligands interact with PD-1 via their immunoglobulin V-like domains. PD-L1 is encoded by the 8-exon CD274 gene on chromosome 9p24.1, is composed of 290 amino acids, and has a molecular weight of 33.3 kDa. Of note, it also competitively binds to B7-1, thus inhibiting the CD28-mediated costimulation of T-cells. [10] PD-L2 is encoded by the 7-exon PDCD1LG2 gene, and is located 42 kilobases apart from the CD274 gene on chromosome 9p24.1. It consists of 273 amino acids, and its molecular weight is 31.0 kDa. [11] The PD-1 signaling pathway PD-1 is present on T-cells as a monomer and is a negative regulator of IL-2 production and T-cell proliferation. [12, 13] PD-1 inhibition of antigen receptor signaling is only seen when PD-1 ligation occurs close to the site of antigen receptor engagement. [13] Indeed, it has been observed that randomly located PD-1 migrates to the immunological synapse during the interaction between T cell and APC. [14] Once PD-1 has bound to ligands, its ITIMs and ITSMs are phosphorylated by the Src-family tyrosine kinases ( Figure 2 ). The phosphorylated tyrosine residue subsequently recruits Src homology 2 domain-containing phosphatases (SHPs), which dephosphorylate signaling intermediates and down-regulate TCR signaling. Of note, ITIM recruits only SHP-2, but ITSM recruits both SHP-1 and SHP-2. [15, 16] SHP-2 appears to be more important than SHP-1 in PD-1 signaling because T cell stimulation with PD-L2 increases the amount of SHP-2 but not of SHP-1. [17] In addition, ITSM is more important than ITIM in PD-1 signaling because PD-1's inhibitory function is lost when ITSM is mutated but not when ITIM is mutated. [15, 18, 19] addition, PD-1's inhibition of the PI3K/Akt pathway prevents T cell's expression of the antiapoptotic protein Bcl-xL, which depends upon PI3K. [20] PD-1 also hinders phosphorylation of ZAP70, an essential molecule for T-cell activation; inhibits activation of PKC-θ, which is critical for IL-2 production, cell cycle progression and T-cell activation; and prevents effector T-cell development by inhibiting glycolysis and promoting fatty acid oxidation. [16, 22, 23] Of note, PD-1 mediated inhibitory signals are inversely associated with the strength of the TCR signal. Furthermore, PD-1 inhibition can be overcome by T cell stimulation with CD28 or exogenous IL-2. [24] The PD-1 pathway plays an important role in enabling tumor cells to evade the immune response. The rate of tumor lysis by cytotoxic T cells (CTLs) in vitro was lower in P815 murine mastocytoma tumor cells with transgenic expression of PD-L1 than in parental tumor cells without PD-L1 expression. Furthermore, inoculating syngenic BALB/c mice with PD-L1 expressing myeloma cells led to more rapid tumor growth, an outcome which was then suppressed by anti-PD-L1 antibodies. [25] Similarly, another study with a mouse model showed that PD-L1 expression in tumor cells confers resistance to activated CTLs but that this effect could be overcome with anti-PD-L1 or anti-PD1 antibodies. [26] In addition, Dong et al's [27] study showed that PD-L1 expression in a melanoma cell line (624mel) enhanced apoptosis of PD-1-expressing CTLs.
Expression of PD-1, PD-L1, and PD-L2 in normal tissue
PD-1 is expressed in activated CD4+ and CD8+ T cells, naïve and activated B cells, myeloid dendritic cells, and with low intensity in monocytes. It is not expressed in resting T cells, but its expression can be induced within 24 hours of T cell activation. [28] In normal human tissue, PD-L1 expression is seen on follicular T-cells, macrophages and a subset of dendritic cells in lymphoid tissue, placental syncytiotrophoblasts, and dendritic cells/monocytes in the lung and liver, although low levels of PD-L1 mRNA are seen in almost all normal tissue. [28] [29] [30] Expression of PD-L2 is more restricted compared with PD-L1. Low levels of PD-L2 expression are seen in activated CD4+ or CD8+ T cell subsets, myeloid dendritic cells, monocytes, endothelial cells, and placental syncytiotrophoblasts. [31] Expression of PD-L1 and PD-L2 is induced by inflammatory signals such as interferon gamma (IFN-γ), granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-4. [27, [32] [33] [34] 
Expression of PD-L1 in lymphoid malignancies
In contrast to the infrequent PD-L1 expression in normal tissue, immunohistochemistry shows that expression of PD-L1 is often found in a variety of cancers. [5] However, the expression pattern of PD-L1 in tumor cells is not uniform. In some tumors, heterogeneous expression of PD-L1 is seen at the interface of the tumor and tumor-infiltrating lymphocytes (TILs). [35] In such cases, PD-L1 expression is likely to be induced by IFN-γ secreted from the TILs. [36] Homogeneous expression of PD-L1 is observed in other tumors, particularly in the Reed-Sternberg (RS) cells of classical Hodgkin lymphoma (CHL). [37] Homogeneous PD-L1 expression usually correlated with intrinsic signals, which are reviewed below. The underlying mechanisms of PD-L1 expression are different in different types of cancer, and antibodies targeting different domains of PD-L1 have been used in various studies (Table 1) . [35, 37, 38] Furthermore, companion diagnostic assays were developed specifically for trials of particular anti-PD1 or anti-PD-L1 agents, including 22C3 for pembrolizumab, 28-8 for nivolumab, and SP142 for atezolizumab. [35, 39, 40] Therefore, PD-1 pathway investigators should pay attention to antibody types when designing a study or interpreting clinical trial results.
As determined by immunohistochemistry, PD-L1 expression is present in CHL; in 87% of CHL cases, irrespective of subtype, over half of RS cells are PD-L1-positive. [41] A recent study demonstrated that almost all (97%) patients with CHL harbored either polysomy, copy-number gain or amplification of 9p24.1 detected by fluorescence in situ hybridization (FISH). [42] In approximately 40% of CHL cases of the nodular sclerosis subtype, the RS cells have copy number alterations (amplifications or gains) and/or translocations involving 9p24.1/PD-L1/PD-L2. [43] Furthermore, Green and colleagues demonstrated that amplification of 9p24.1 not only increases the genetic dosage of PD-L1/PD-L2 but also induces JAK2 amplification and, consequently, enhancement of JAK/STAT signaling. [43] Since PD-L1 has a promoter which is responsive to Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, extra signaling for PD-L1 expression is present in CHL. Advanced stage (stages III/IV) CHL patients with 9p24.1 amplification have significantly shorter progression-free survival. [42] Copy number alterations and/or translocations involving 9p24.1/PD-L1/PD-L2 are also frequently seen in patients with primary mediastinal large B-cell lymphoma (PMBL) (~70%), EBV-negative primary central nervous system lymphoma (PCNSL) (~60%), and primary testicular lymphoma (PTL) (~60%). [43, 44, 45] Immunohistochemistry shows that approximately 70%, 50% and 50% of PMBL, PCNSL and PTL tumors, respectively, express PD-L1, supporting the idea that PD-L1 expression is induced by cytogenetic abnormalities. [41, 44] In DLBCL, not otherwise specified (DLBCL, NOS), PD-L1 expression is seen in 11-26% of cases by immunohistochemistry. [41, 46, 47] Interestingly, a similar percentage (~20%) of cytogenetic abnormalities in 9p24.1 (gains, amplifications or translocations) is also observed in these cases. [43, 46, 47] Gains and amplifications of 9p24.1 and translocations of PD-L1 correlate with increased PD-L1 mRNA expression and PD-L1 protein expression.
Furthermore, cytogenetic abnormalities in 9p24.1 and PD-L1 protein expression are associated with activated B-cell-like or non-germinal center B cell-like phenotype of DLBCL, as determined by gene expression profiling and Hans classification, respectively. [46, 47] A Japanese study determined that PD-L1 expression in DLBCL is an independent indicator of poor prognosis. [47] Available data suggest that, in DLBCL patients, the PD-1 pathway could be an immune escape mechanism and that patients with PD-1 expression could be good candidates for anti-PD-1 or anti-PD-L1 therapies.
EBV provides an intrinsic signal to augment PD-L1 expression. EBV latent membrane protein 1 (LMP1) activates the JAK/STAT pathway and the transcription factor AP-1; this enables JAK3 to activate a PD-L1 promoter and AP-1 to stimulate a PD-L1 enhancer. [48] [49] [50] Chen et al. [41] have shown that PD-L1 expression in RS cells is more commonly present in EBV-positive CHL than in EBV-negative CHL. Similarly, PD-L1 expression is seen in all cases of EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) and EBVpositive immunodeficiency-related DLBCL. [41] Unlike EBV-negative PCNSL, EBVpositive PCNSL frequently express PD-L1 without 9p24.1/PD-L1/PD-L2 copy number alterations, suggesting that PD-L1 expression is induced by viral proteins. [44] Other EBVassociated lymphoproliferative disorders including EBV+ post-transplant lymphoproliferative disorder (PTLD), plasmablastic lymphoma, primary effusion lymphoma, and extranodal NK-T-cell lymphoma express PD-L1 in approximately 60%, 50%, 50% and 70%, respectively. [41, 50] Chen and colleagues showed that 91% of T-cell rich, histiocyte-rich large B-cell lymphomas (TCHRBCLs) express PD-L1, compared to only 13% of nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs). [41] Since TCHRBCL and NLPHL have considerable morphologic overlap but opposite clinical behaviors, this finding is very intriguing. [51] One can speculate that acquiring PD-L1 expression is an immune escape mechanism of indolent NLPHL and that leads to more aggressive TCHRBCL. Of note, histiocytes adjacent to lymphoma cells also show strong PD-L1 expression in TCHRBCL, suggesting that both tumor cells and background inflammatory cells provide immune escape signals. [41] Since 9p24.1 aberrations and EBV infection are not generally seen in TCHRBCL, PD-L1 is thought to be induced by IFN-γ secreted from tumor-infiltrating T-cells. [52] Another intrinsic mechanism of increased PD-L1 expression was revealed by Kataoka and colleagues, who showed that increased PD-L1 expression is associated with PD-L1 3′untranslated region (UTR) disruption in about 30% and 10% of adult T-cell leukemia/ lymphoma patients and DLBCL patients, respectively. [53] Of interest, PD-L1 expression induced by 3′-UTR disruption with truncated protein was only seen when an antibody was directed against the extracellular domain and not when an antibody was directed against the cytoplasmic domain. Whether 3′-UTR disruption in PD-L1 is present in other lymphoid neoplasms is still unknown.
PD-L1 expression also occurs through constitutive activation of the JAK/STAT pathway. In ALK+ anaplastic large cell lymphoma with NPM-ALK rearrangement, the fusion transcript has been shown to induce expression of PD-L1 via STAT3 activation. [54] Furthermore, PD-L1 expression in DLBCL correlates the ABC phenotype, which is known for its enhanced JAK/STAT pathway. [55] PD-L1 expression in myeloma cells can be detected by flow cytometry. [56] Significant increase in copy number of PD-L1 and PD-L1 mRNA expression is seen in malignant myeloma cells, which correlates with PD-L1 expression in myeloma cells. [56] Compared with normal plasma cells, PD-L1 expression is up-regulated in non-hyperdiploid and hyperdiploid myeloma cells, with higher expression in the latter. However, PD-L1 expression is not associated with del (1q), del (13) , del(17p), t(11;14), t(4;14) or t(14;16).
PD-L1 expression is not generally seen in follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma. [57, 58] 
Expression of PD-L2 in lymphoid malignancies
Lymphoid neoplasms with abnormalities in 9p24.1/PD-L1/PD-L2 generally express PD-L2. RS cells in CHL also express PD-L2, irrespective of EBV status. [59] PD-L2 expression by immunohistochemistry occurs in 72% of PMBL, and copy number gain of PDCD1LG2 gene has also been observed in most cases. [60] PD-L2 expression is also present in PTLs and PCNSLs, which are associated with 9p24.1/PD-L1/PD-L2 copy gains or translocations. [44] However, unlike PD-L1 expression, PD-L2's expression of RNA and protein were not associated with cytogenetic abnormalities in 9p24.1 in DLBCL, NOS. [46] Also, PD-L2 expression is not associated with EBV infection or 3′-UTR disruption in the PD-L1 gene. [53, 57] 
Expression of PD-1 in the lymphoid malignancy microenvironment
Although PD-1 expression is seen in a few lymphoid malignancies, particularly T cell lymphomas with the follicular helper T cell phenotype, most lymphoid neoplasms do not express PD-1. [30, 61] Thus, PD-1 expression is best examined in the microenvironment. PD-1 expression in TILs has been reported in follicular lymphoma, and NLPHL is well known for PD-1-expressing T-cell rosettes surrounding neoplastic L&H cells (LP cells or popcorn cells). [62, 63] Since both neoplasms arise from germinal center B cells, it is not surprising that their microenvironments are like those of their normal counterparts. Likewise, PD-1-expressing TILs are also correlated with DLBCL, germinal center B-celllike (GCB) phenotype. [47] Interestingly, the high number of PD-1-expressing TILs in the DLBCL microenvironment is inversely associated with PD-L1 expression in lymphoma cells. Furthermore, contrary to observations in solid tumors, the high number of PD-1expressing TILs in DLBCL and in follicular lymphoma (FL) is associated with a favorable prognosis; this suggests that the presence of PD-1-expressing TILs in lymphomas could simply indicate cell-of-origin, unlike tumor-mediated T-cell exhaustion in solid tumors. [47, 62, 64, 65] 
Anti-PD-1 antibodies Pembrolizumab (Keytruda®, MK-3475, SCH 900475, previously lambrolizumab)
Pembrolizumab is a fully humanized IgG4 kappa isotype anti-PD-1 monoclonal antibody. It is well tolerated and is associated with durable anti-tumor activity in multiple solid tumors. [66] In a phase 1b study (KEYNOTE-013 study, NCT01953692), pembrolizumab was administered to 31 patients with CHL every 2 weeks (10 mg/kg IV) until disease progression. [67] The median age was 32 years (range, 20-67 years). Seventeen (55%) patients had ≥ 5 lines of prior therapy, 31 (100%) failed with brentuximab vedotin (BV) treatment, 22 (71%) underwent prior autologous stem cell transplant (ASCT), and 8 (26%) were ineligible for transplantation. Examination of formalin-fixed, paraffin-embedded tissue revealed PD-L1 (clone 22C3) and PD-L2 (clone 3G2) expression in 94% and 90% of tested patients, respectively, before pembrolizumab treatment. With the median follow-up of 17.6 months (range, 10.6-22.5 months), the overall response rate (ORR) was 65%, with 5 (16%) and 15 (48%) patients achieving complete remission (CR) and partial remission (PR), respectively. Among the 20 patients, 16 (80%) achieved their best response around 12th Ok week of therapy and 14 (70%) had ≥ 24 weeks of duration. The progression-free survival (PFS) rates were 69% and 46% at 24 weeks and 52 weeks, respectively. By flow cytometry, expansion of circulating total T cells, including CD4+ and CD8+ T cells, and NK cells was observed at cycle 7 compared to baseline. RNA profiling showed significant increases in the IFN-γ-induced, expanded immune-related, and TCR signatures. [67] A multicohort phase 2 study is underway (KEYNOTE-087, NCT02453594) to confirm the clinical activity of pembrolizumab in CHL patients. Patients, all of whom have relapsed/ refractory CHL, are in 3 cohorts of those who: (1) had an ASCT and subsequent BV therapy, Table 2 lists numerous ongoing clinical trials of pembrolizumab given as a single therapy or in combination with other therapies.
Nivolumab (Opdivo®, BMS-936558, MDX-1106, ONO-4538)
Nivolumab is a fully human IgG4 anti-PD-1 monoclonal antibody. It has a high affinity for PD-1 and blocks it from binding to its ligands. Like pembrolizumab, it is well tolerated and is associated with durable anti-tumor activity in solid tumors. [71] In a phase 1b study, 23 patients with relapsed/refractory CHL in whom ASCT and BV was unsuccessful, received 3 mg/kg nivolumab at week 1, week 4, and then every 2 weeks until disease progression or CR or for a maximum of 2 years (NCT01592370). [37] The median age was 35 years (range, 20-54 years). Twenty (87%) patients had received ≥ 3 lines of prior therapies, 18 (78%) had received BV, and 18 (78%) had undergone ASCT. Ten (43%) patients were tested for PD-L1 and PD-L2 with FISH, and all had polysomy 9p and gain or amplification of PD-L1/PD-L2. Table 2 lists numerous ongoing clinical trials of nivolumab given as a single therapy or in combination with other therapies.
Although the drug showed positive results in patients with follicular lymphoma and DLBCL, its mechanism of action needs to be elucidated. [77, 78] 
Anti-PD-L1 antibodies
There are several ongoing clinical trials with anti-PD-L1 antibodies (atezolizumab, durvalumab, avelumab and CA-170) in patients with lymphoid neoplasms, but results have not been published yet (Table 2 ).
Anti-PD-1/PD-L1 agents in combination with other treatments
Anti-PD-1/PD-L1 antibodies can be combined with other treatments in a myriad of ways. Clinical trials of anti-PD-1/PD-L1 antibodies combined with standard chemotherapy, targeted therapy (i.e., rituximab or BV) or ASCT are plentiful ( Table 2 ). In this review, we will discuss several approaches to combination therapy with anti-PD-1/PD-L1 antibodies.
One of the strategies is to combine an anti-PD-1 antibody with an agent that blocks another co-inhibitory molecules (e.g. CTLA-4 or lymphocyte activation gene 3 [LAG-3]) in T cells. Clinical trials of nivolumab combined with ipilimumab (an anti-CTLA-4 inhibitor) or BMS-986016 (an anti-LAG-3 inhibitor) are underway in patients with hematologic malignancies ( Table 2) . A similar approach is to combine anti-PD-1/PD-L1 antibodies with urelumab, a cytotoxic T cell-activating drug that binds CD137. The intent of this approach is not to block two different co-inhibitory molecules; rather, it is to simultaneously enhance CTL activity and block inhibitory signals. Preclinical studies have demonstrated that this combination of anti-PD-1/PD-L1 antibodies and urelumab enhances the anti-tumor activity of T cells. [26, 79] A phase 1 clinical trial of nivolumab plus urelumab is now under way in patients with advanced B-cell non-Hodgkin lymphoma.
Combination therapy with anti-PD-1/PD-L1 antibodies can involve modulating the immunosuppressive tumor microenvironment. Epigenetic modifying agents disrupt the immunosuppressive tumor microenvironment by eradicating myeloid-derived suppressor cells or enhancing the effector function of T-and NK cells. [80, 81] Furthermore, treating a human leukemia cell line with a hypomethylating agent has been shown to augment PD-L1 and PD-L2 expression. [82] Therefore, combining epigenetic modifying agents with anti-PD/PD-L1 antibodies is a sensible approach. Indeed, preclinical and clinical studies report promising results. [83, 84] Several clinical trials are under way ( Table 2 ).
In a melanoma mouse model, the tumor-intrinsic, active Wnt/β-catenin pathway induces T cell exclusion in the tumor microenvironment and resistance to anti-PD-L1 antibodies. [85] The kinases FAK and PYK2 augment Wnt/β-catenin pathway, and a preclinical study has shown that combining a FAK/PYK2 dual inhibitor (VS-4718) with an anti-PD-1 monoclonal antibody is more effective than anti-PD-1 therapy alone and extended survival in vivo. [86] Combining VS-4718 and an anti-PD-1 monoclonal antibody also increases the CD8+ T cell: regulatory T cells ratio, suggesting an attractive approach to modulating the tumor microenvironment to enhance the anti-tumor activity of anti-PD-1 antibodies. [87] Patients with plasma cell myeloma could be potential candidates because VS-4718 alone already has been shown to inhibit myeloma cell growth in vitro and in vivo. [88] It is noteworthy that the administration of AFM13 and an anti-PD1 agent using an autologous PDX mouse model with donor-matched tumors and peripheral blood mononuclear cells from patients with Hodgkin lymphoma showed synergistic anti-tumor effect. AFM13 is a bi-specific, anti-CD30/CD16A, tetravalent chimeric antibody construct that targets CD30-expressing malignancies by recruiting NK cells. [89] Compared to monotherapy with anti-PD1, combined therapy with AFM13 initially enhances the infiltration of macrophages and activated NK cells and later enhances T cells and dendritic cell infiltration. [90] Based on this information, a clinical study of combined AFM13 and pembrolizumab in relapsed/refractory CHL is in preparation.
Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective in patients with lymphoma, and blocking the PD-1 pathway in combination with CAR T cell therapy is an interesting approach. [91] A phase 1 study of durvalumab and anti-CD19 CAR T cell therapy will soon enroll patients with relapsed/refractory DLBCL. Oncolytic viral therapy activates innate immune responses against virally infected tumor cells and enhances adaptive anti-tumor immune responses by in vivo priming against tumor-associated antigens. A melanoma mouse model study of oncolytic vital therapy combined with anti-PD-1 or anti-CTLA-4 demonstrated significant anti-tumor activity, providing a rationale for clinical studies. [92] Immune-related adverse events Thanks to the clinical success of nivolumab and pembrolizumab in solid tumors, the list of tumors treatable with anti-PD-1 or anti-PD-L1 antibodies is expanding. Therefore, clinicians would observe more patients with immune related adverse events (irAEs). Overall, grade 3 or 4 irAEs are observed in 7-12% of patients with solid tumors who receive single anti-PD-1 or anti-PD-L1 antibodies. [39, 93] Of note, a predictable pattern of irAEs has been observed in such patients; dermatologic and gastrointestinal toxicities appear early, and hepatic toxicities or endocrinopathies are seen later. [94] In patients with lymphoid neoplasms, irAEs of any grade appear in 72%-100% of patients. [37, 67, 69, [72] [73] [74] The management of irAEs depends on their severity. Patients with grade 1 irAEs may continue PD-1-targeted therapy if symptoms are not observed, but it is recommended to withhold anti-PD-1 therapy from those with grade 2 irAEs and to manage symptoms with oral prednisone (1mg/kg/day) or an equivalent drug. Patients with irAEs of grade 3 or higher should discontinue anti-PD-1 therapy and be treated with intravenous methylprednisolone (2-4mg/kg/day) or an equivalent drug. Daily monitoring with liver function test is also recommended. [95] 
Conclusion
Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. PD-L1 expression in normal tissue is limited, but its expression in tumor cells can be induced by extrinsic signals (e.g., IFN-γ). In various lymphoid neoplasms, PD-L1 expression can also be induced by intrinsic signals, including 1) genetic aberrations involving 9p24.1 encompassing PD-L1, PD-L2 and JAK2; 2) latent EBV infection, particularly by LMP1; 3) PD-L1 3′-UTR disruption; and 4) the activated JAK/STAT pathway. Clinical use of PD-1pathway-blocking agents has successfully treated some lymphoid neoplasms, particularly those with PD-L1 expression induced by intrinsic signals. Currently, combination therapies involving anti-PD-1/PD-L1 agents and conventional chemotherapies, targeted therapies, or other immunotherapies are being studied, and we expect that the resulting data will broaden our understanding of the PD-1 pathway and expand the list of patients who will benefit from PD-1-pathway-blocking agents to include those who suffer from lymphoid neoplasms. The two-signal model of T-cell activation. The first signal is a processed antigen presented by the MHC molecule of an APC to TCR of a T cells. This triggers TCR signaling, which is modulated by the antigen-independent co-stimulatory or co-inhibitory signals delivered by APCs. The T cell molecules CD28, PD-1, and CTLA-4 bind to B7-1/B7-2, PD-L1/PD-L2 and B7-1/B7-2, respectively. CD28, when engaged with its ligands, induces cell cycle progression, interleukin-2 production and clonal expansion. In contrast, PD-1 and CTLA-4 induces T cell tolerance when engaged with their respective ligands. APC, antigen-presenting cells; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; MHC, major histocompatibility complex; TCR, T cell receptor; PD-1, programmed death 1; PD-L1/2, programmed death-ligand 1 or 2, +, activation of the pathway; −, inhibition of the pathway. Ok Clinical trials involving anti-PD-1 or anti-PD-L1 antibodies 
